The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential ...

PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO ...

A team of researchers led by University of California, Riverside biomedical scientists has identified a small, previously ...

A team of researchers led by University of California, Riverside biomedical scientists has identified a small, previously overlooked small RNA molecule that plays a major role in controlling the ...

Department of Biochemistry and Molecular Medicine, University of California at Davis, School of Medicine, Sacramento, CA, United States Small RNA or oligonucleotide therapeutics represent a unique ...

Although amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). are very different diseases, they have something in common: overexcited neurons. Neurons send crucial signals that allow ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform. Alloy is ...

Background and Purpose— The present study was performed to determine whether antisense inhibition of intercellular adhesion molecule-1 (ICAM-1) protein expression decreases focal ischemic brain damage ...

Michael Sitzman joined McDermott Will & Emery as a partner in its intellectual property practice group in San Francisco, the firm announced Tuesday. Sitzman represents biotechnology and brand-side ...

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development of AS-241, an investigational treatment strategy for amyotrophic ...